FDA Approves MiniMed 670G System – World’s First Hybrid Closed Loop System
the first hybrid closed loop system in the world!
This approval is a significant milestone in the history of diabetes management, and a culmination of many years of dedicated work. With this approval, we are one step closer to delivering a fully automated closed loop system.
You may be wondering how this system is different from the MiniMed 630G system we recently launched in the U.S.
Advanced SmartGuard Technology
The MiniMed 670G system features our most advanced algorithm to date – SmartGuard HCL – which simplifies and improves diabetes management through a smart algorithm that enables greater glucose control with reduced user input. Through SmartGuard HCL, the system builds on Medtronic’s industry leading algorithms to offer therapy customization so people with diabetes and providers can choose from increasing levels of automation that best fit their diabetes management needs.
Driven by the SmartGuard HCL, the system delivers a variable rate of insulin 24 hours a day based on the personalized needs of the individual, maximizing the time glucose levels are within the target range. It is designed to learn what an individual’s insulin needs are and to take action to minimize both high and low glucose levels. As a result, the system requires minimal input – users only need to enter mealtime carbohydrates, accept bolus correction recommendations, and periodically calibrate the sensor.
New Guardian Sensor
The system uses our new Guardian Sensor 3, our most advanced and accurate glucose sensor. The sensor offers seven-day continuous wear and incorporates diagnostic t Continue reading